Our Management board currently consists of seven members. The international composition and the varied responsibilities reflect our global operations.
Rice Powell (62) is chief executive officer and chairman of the management board effective January 1, 2013. Prior to that, he was vice chairman of the management board and member of the management board responsible for the region North America from 2010 to 2012. He joined Fresenius Medical Care in 1997 and was appointed to the company's management board and Co-CEO of Fresenius Medical Care North America in January 2004. He has over 36 years of experience in the healthcare industry. From 1978 to 1996, he held various positions, among others at Baxter International Inc. and Biogen Inc. in the U.S.
Michael Brosnan (62) was appointed chief financial officer on January 1, 2010. Previously, he served as chief financial officer of Fresenius Medical Care North America for seven years. He joined the company in 1998 as vice president of Finance and Administration for Spectra Renal Management, the company’s laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America. Prior to joining the company, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG.
Dr. Olaf Schermeier (45) was appointed chief executive officer for Global Research and Development on March 1, 2013. Previously, he served as president of global R&D for Draeger Medical, Lübeck, Germany. Dr. Schermeier has many years of experience in various areas of the health care industry, among others at Charité-clinic and Biotronik, Germany. He holds a doctorate degree (PhD) in Computer Science from the Technical University of Berlin, Germany and graduated from the University of Hannover, Germany in Electrical Engineering.
William Valle (56) was appointed chief executive officer for North America effective February 17, 2017. Prior to that, he was executive vice president responsible for the dialysis service business and vascular access business of Fresenius Medical Care North America from 2014 to 2017. Bill joined Fresenius Medical Care in 2009 and has nearly 30 years of experience in the dialysis industry, holding executive positions in sales, marketing and business development at several dialysis companies including Gambro Healthcare, Inc.
Kent Wanzek (58) was appointed chief executive officer for Global Manufacturing & Quality on January 1, 2010. From 2004 onwards, he was in charge of North American operations for the Renal Therapies Group at Fresenius Medical Care North America. Prior to joining the company in 2003, he held several senior executive positions at Philips Medical Systems, Perkin Elmer and Baxter Healthcare Corporation, among others.
Europe, Middle East and Africa, and labor relations director Germany
Dominik Wehner (49) was appointed chief executive officer for Europe, Middle East and Africa (EMEA) on April 1, 2014. He has also been appointed labor relations director for Germany. He began his career at Fresenius Medical Care in 1994 as junior sales manager. Before being appointed to the company's management board he served as executive vice president responsible for the regions Eastern Europe, Middle East and Africa as well as Renal Pharma Europe, Middle East, Africa and Latin America EMEALA and P. O. I. (People, Organizational Change and Implementation) EMEALA. He also serves on the Vifor Fresenius Medical Care Renal Pharma Ltd. board of directors.
Harry de Wit (55) was appointed Chief Executive Officer for Asia-Pacific on April 1, 2016. He has worked in various areas in the medical device industry for over 25 years. Previously, Mr. de Wit served as President Asia at Covidien (now Medtronic) in Singapore. He holds a Master’s degree in Medicine from the VU University of Amsterdam, the Netherlands and a Bachelor’s of Science in Physiotherapy from the School of Physiotherapy of Den Bosch, Netherlands.